Immunotherapy drug shows limited promise in tough bile duct cancer
NCT ID NCT02829918
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested the immunotherapy drug nivolumab (Opdivo) in 54 patients with advanced biliary tract cancer that had stopped responding to chemotherapy. The goal was to see if the drug could shrink tumors. While nivolumab is approved for other cancers, it is not yet approved for this type. The study measured how many patients responded after four cycles of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nivolumab (Opdivo), a cancer immunotherapy drug
What this could lead to
If successful, this could point toward a new treatment option for patients with advanced biliary tract cancer who have run out of standard therapies.
What could go wrong
This is a small, early-phase trial (54 patients) with no control group. The drug may not work for most patients, and side effects from immunotherapy can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Cancer Center
Duarte, California, 91010, United States
-
Emory University Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States